GLUE
NASDAQ · Biotechnology
Monte Rosa Therapeutics Inc
$12.61
+0.01 (+0.08%)
Open$12.80
Previous Close$12.60
Day High$12.81
Day Low$12.54
52W High$25.77
52W Low$6.16
Volume—
Avg Volume1.20M
Market Cap1.06B
P/E Ratio—
EPS$-1.74
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+204.9% upside
Current
$12.61
$12.61
Target
$38.45
$38.45
$28.40
$38.45 avg
$50.36
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 130.67M | 401.98M | 400.93M |
| Net Income | -40,815,396 | -29,192,444 | -34,329,564 |
| Profit Margin | -31.2% | -7.3% | -8.6% |
| EBITDA | -48,451,824 | -51,685,540 | -47,809,490 |
| Free Cash Flow | — | -50,874,519 | -44,333,819 |
| Rev Growth | — | +22.8% | -9.2% |
| Debt/Equity | — | 0.43 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.08 | -0.05% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $406.09 | -1.01% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $151.37 | -0.85% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $516.34 | +0.26% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $801.82 | -0.26% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $246.51 | -2.04% | 40.0 | 32.33B |